Locus and allelic heterogeneity in five families with hereditary spastic paraplegia

Malavika Hebbar¹ · Anju Shukla¹ · Sheela Nampoothiri² · Stephanie Bielas³ · Katta M Girisha¹

Received: 10 April 2018 / Revised: 12 September 2018 / Accepted: 8 October 2018 / Published online: 18 October 2018
© The Author(s) under exclusive licence to The Japan Society of Human Genetics 2018

Abstract
Hereditary spastic paraplegias are a group of genetically heterogeneous neurological disorders characterized by progressive weakness and spasticity of lower limbs. We ascertained five families with eight individuals with hereditary spastic paraplegia. Pathogenic variants were identified by exome sequencing of index cases. The cohort consists of three families with spastic paraplegia type 47 (AP4B1) with a common mutation in two families, a family with spastic paraplegia type 50 (AP4M1), and two male siblings with X-linked spastic paraplegia 2 (PLP1). This work illustrates locus and allelic heterogeneity in five families with hereditary spastic paraplegia.

Introduction
Hereditary spastic paraplegia (HSP) are a group of neurological disorders predominantly affecting lower limbs in a progressive manner resulting in weakness and spasticity [1]. The prevalence of HSP is estimated to be around 1.8/1,00,000 general population [2]. The diagnosis of HSP is based on the presence of slowly progressive bilateral lower limb spasticity and weakness, signs of corticospinal tract involvement such as hyperreflexia and extensor plantar responses [3]. Complicated HSP is characterized by spastic paraplegia associated with other abnormalities like seizures, ataxia, intellectual disability, peripheral neuropathy, or extrapyramidal involvement. HSPs illustrate one of the highest degree of genetic heterogeneity involving more than 70 genetic subtypes, demonstrating all patterns of Mendelian inheritance (autosomal dominant, autosomal recessive, X-linked) and mitochondrial inheritance [3, 4]. We ascertained five families with eight individuals with HSP. Exome sequencing, Sanger validation, and segregation analysis were carried out in all these families.

Methods
We ascertained five unrelated Indian families with eight affected individuals with HSP. Subjects were evaluated at genetics clinic where patients with neurological disorders were studied under the projects titled, ‘Clinical and molecular characterization of leukodystrophies in Indian children’ and ‘Genetic Diagnosis of Heritable Neurodevelopmental Disorders in India: Investigating the Use of Whole Exome Sequencing and Genetic Counseling to Address the High Burden of Neurodevelopmental Disorders’. Patients with HSP were selected from these research projects. Informed consent was obtained for the use of clinical and research findings for publication. The study has the approval from Institutional Ethics Committee. Exome sequencing was performed in all the families. Sanger sequencing was performed to validate the variants and to determine the segregation in the families. Exome sequencing was performed on leukocyte-derived genomic DNA using Illumina’s Nextera Rapid Capture Exome Kit on the Illumina NextSeq Platform (Illumina, San Diego, California, USA) [5]. The average coverage depth was
130x, with ~95% of the bases covered at >20x, and a sensitivity of >90%. Data were stored and analyzed using a reported automated pipeline, SeqMule v1.2.5 [6]. The variant call format file was annotated by ANNOVAR v.2016Feb01 [7]. Variants were filtered to 1% allele frequency in population databases including ExAC, 1000 genome database, and an internal database of exomes of 427 individuals of Indian origin. Exonic and splice-site variants were then prioritized by MIM (Mendelian Inheritance in Man) identity, phenotypic assessment, and the American College of Medical Genetics (ACMG) criteria of pathogenicity [8].

Results

Clinical descriptions

Family 1

P1 was evaluated at 14 years of age. She is the first-born child to a fourth-degree consanguineous marriage (Fig. S1A). She was born at term with a birth weight of 2.45 Kg (−1 SD). She achieved neck holding at 5 months of age, sat without support at 9 months and started speaking bisyllables at 3 years followed by standing and walking at 3 years of age. On exam, she weighed 35 Kg (at 3 years followed by standing and walking at 3 years of age and has not attained speech. There were no seizures in him. Parents complained of frequent falls and drooling. His weight was 11 Kg (−2 SD), OFC 44 cm (−5 SD) and height 95 cm (−1 SD) at 4 years. He was not dysmorphic. He has an unsteady gait and walked on toe tips. Bilateral contractures of tendoachilles was noted. High resolution karyotype revealed a karyotype of 46,XYqter+. Magnetic resonance imaging of brain showed hypoplastic corpus callosum (Fig. S2B).

P2 is a 13-years-old male sibling of P1. He had similar complaints and facial appearance as his elder sister. He weighed 1.75 Kg (−3 SD) at birth. Developmental milestones were delayed. He achieved neck holding at 3 months of age, crawled at 3 years, sat without support at 4 years, and spoke bisyllables at 13 years. He is non-ambulatory. Examination revealed an OFC of 46 cm (−5 SD), height 117 cm (−5 SD) and weight 17 Kg (−5 SD). He also had post-axial polydactyly on left hand and both feet, broad great toes, contractures at knee and ankle joints, spasticity, and exaggerated deep tendon reflexes. Ultrasonography of abdomen and pelvis were unremarkable. Magnetic resonance imaging of brain revealed thin splenium of corpus callosum and periventricular white matter abnormalities (Fig. S1C, S1D).

Family 2

P3 and P4 are male siblings. Their parents were consanguinely married (third degree) (Fig. S2A). P3 was evaluated at 4 years of age. He had an uneventful birth history and neonatal period. His weight at birth was 2.6 Kg (+1 SD). He had global developmental delay. He walked at 4 years of age and has not attained speech. There were no seizures in him. Parents complained of frequent falls and drooling. His weight was 11 Kg (−2 SD), OFC 44 cm (−5 SD) and height 95 cm (−1 SD) at 4 years. He was not dysmorphic. He has an unsteady gait and walked on toe tips. Bilateral contractures of tendoachilles was noted. High resolution karyotype revealed a karyotype of 46,XYqter+. Magnetic resonance imaging of brain showed hypoplastic corpus callosum (Fig. S2B).

P4 is a 1-year-old boy with unremarkable birth history. He weighed 2.8 Kg (+1 SD) at birth. He attained head control at 4 months, sits with support at present. He had an episode of febrile seizure. His anthropometry showed an OFC of 44 cm (−3 SD), height of 75 cm (−1 SD), weight, 9.5 Kg (−1 SD). He had coarse facies, broad forehead, hypertelorism, short nose, anteverted nares, long philtrum. Other findings on exam were hypotonia, bilateral undescended testes. Creatinine kinase (CK) levels were normal. GCMS, sub-telomeric MLPA were unremarkable. Magnetic resonance imaging of brain revealed hypoplastic corpus callosum.

Family 3

P5 was second born to a non-consanguineous marriage and evaluated at 2 years (Fig. S3A). Birth history and neonatal period was normal. He weighed 3 Kg (+2 SD) at birth. Neck holding and partial roll over was achieved before 6 months of age. He does not sit. He had 3–4 episodes of generalized tonic-clonic seizures daily starting from age 6 months and was on antiepileptic drugs. At age 2 years, his OFC was 40.5 cm (−6 SD), length was 76 cm (−3 SD), weight 8.5 Kg (−3 SD). Deep tendon reflexes were diminished, and tone was variable. His hematology and urine routine examinations revealed normal results. Hypoplasia of corpus callosum and periventricular white matter abnormalities were observed on magnetic resonance imaging of brain (Fig. S3B, S3C).

Family 4

P6 was 6 years when she was evaluated. She was the first born to a consanguineous marriage (Fig. S4A). She was noted to have developmental delay and seizures (precipitated by fever). At age 6 years she spoke disyllables and stood with support. She was not toilet trained. She was noted to have microcephaly (OFC 42 cm, −3 SD), mild
facial dysmorphism comprising sagging cheeks and downturned corners of the mouth. Hypotonia, joint laxity in upper limbs, spasticity of lower limbs and contractures at knees were observed. Magnetic resonance imaging of brain showed mild prominence and asymmetry of the lateral ventricles, mild hypoplasia of posterior part of the body of corpus callosum (Fig. S4B and S4C).

**Family 5**

P7 and P8 are male siblings aged 19 and 17 years respectively, born to non-consanguineous family (Fig. S5A). Both had global developmental delay. P8 achieved roll over at 1 year and walked with support at 2.5 years. Both were noted to have progressive difficulty in walking and feeding difficulty. Both of them had normal growth parameters. P8 had brisk deep tendon reflexes, spasticity, contractures, extensor plantar response, and distal joint laxity. Magnetic resonance imaging of brain was unremarkable. P7 had a similar but milder phenotype as compared to P8.

**Molecular analysis**

Molecular findings in the affected individuals from all the six families are summarized in Table 1. Family 1, family 2, and family 3 (Fig. S1E, S2C, S3D) were diagnosed with spastic paraplegia type 47 (#MIM 614066). Family 2 and 3 had the same genotype, c.304 C>T, p.(Arg102Ter). P6 from family 4 was noted to have a canonical splice-site variant, c.1026-1G>T in AP4M1 (Fig. S4D) causing spastic paraplegia type 50 (#MIM 615905). A known pathogenic variant, c.2T>G, p. Met1Arg in PLP1 was identified in family 5 with X-linked spastic paraplegia 2 (#MIM 312920) [9] (Fig. S6B). We report two novel and two known variants. All the variants were not observed in homozygous state in population databases like 1000 Genomes Project, ExAC database and in-house data of 437 exomes and occur at highly conserved amino acids sequence. One was a canonical splice-site variant (AP4B1) and another frameshift deletion (AP4B1). Other novel variants were missense changes. In-silico analysis tools were consistent in predicting that they may damage the protein function. Clinical findings observed in the patients were in concordance with respective phenotypes caused due to these variations. Biallelic segregation and validation of the variants were done by Sanger sequencing. The missense variants therefore fell into the category, “likely pathogenic” according to ACMG criteria.

**Discussion**

Currently, HSP is a syndromic designation for a clinically and genetically heterogeneous group of inherited

| Family | Patient | Gene | Variants | Transcript ID | CADD score | GERP score | Known/Novel variant | Zygosity | Phenotype | OMIM number |
|--------|---------|------|----------|---------------|------------|------------|---------------------|----------|-----------|-------------|
| 1      | 1.2     | AP4B1 | c.1181_1182del, p.(Gln394ArgfsTer23) | NM_001253852.1 | NA         | NA         | Novel               | Homozygous | spastic paraplegia type 47 | 614066     |
| 2      | 3.4     | AP4B1 | c.304C>T, p.(Arg102Ter) | NM_001253852.1 | 36         | 3.36       | Known              | Homozygous | spastic paraplegia type 47 | 614066     |
| 3      | 5.6     | AP4B1 | c.304C>T, p.(Arg102Ter) | NM_001253852.1 | 36         | 3.36       | Known              | Homozygous | spastic paraplegia type 47 | 614066     |
| 4      | 7.8     | PLP1  | c.2T>G, p.Met1Arg | NM_000533.3 | 13.24      | 5.44       | Known              | Homozygous | X-linked spastic paraplegia 2, 312920 | 615905 |
neurodevelopmental disorders in which the main symptoms and signs are weakness and spasticity of the lower limbs primarily due to retrograde dysfunction of the descending fibers of the corticospinal tract [3]. With an increasing number of genetic etiologies, it poses a significant challenge for diagnosis of these conditions in the clinic.

We observed three families with five affected individuals aged 1–14 years with spastic paraplegia 47. All of them had classical symptoms of SPG47 [3, 10, 11]. Family 1 (P1 and P2), family 2 (P3 and P4) and family 3 (P5) presented with global developmental delay, progressive difficulty in walking and speech delay in the probands. Additionally, facial dysmorphism was noted in P1 and P2 of family 1. P5 also had generalized tonic-clonic seizures at the time of presentation. Age-related progression was striking as the younger patients P4 and P5 displayed generalized hypotonia with diminished reflexes and the older patients P1, P2, and P3 manifested contractures and spasticity. Hypoplasia of corpus callosum was the most common brain imaging finding in all of them with periventricular white matter abnormalities in P2 and P5. As reported in the literature earlier, we too observed loss-of-function variants (frameshift and nonsense) in our patients [10–13]. Family 2 and family 3 shared the same nonsense variant. We identified another novel frameshift variant, c.1181_1182del, p. (Gln394ArgfsTer23) and a reported nonsense variant, c.304C>T p.(Arg102Ter) in AP4B1 [14].

Autosomal recessive HSP due to pathogenic variants in AP4M1 (Spastic paraplegia 50) is a rare neurodevelopmental disorder reported for only a few patients. Seven pathogenic AP4M1 mutations in seven families have been reported to date [15]. Copy number variants including the AP4M1 have also been implicated in developmental anomalies [16]. The spectrum of clinical findings observed in the patients in the literature are of infantile hypotonia, intellectual disability, developmental delay, early-onset spastic paraplegia, variable white matter, and cerebellar involvement on brain MRI [17–21]. A genotype–phenotype correlation has been proposed earlier as early onset and severe phenotype was often noted in individuals with truncating variants in comparison to missense variants in individuals with milder phenotype [15]. Proband in family 4 (P6) possessed a canonical splicing variant and manifested classical signs of AP-4 complex deficiency like seizures (precipitated by fever), distinctive facial appearance, hypotonia, developmental delay, early-onset spastic paraplegia and signs of cerebellar volume loss.

Pathogenic variants in the PLP1 have been identified in families with X-linked recessive spastic paraplegia type 2 and Pelizaeus-Merzbacher disease. Multiple affected males from a large French–Canadian family is reported with early with developmental delay and progressive spastic paraplegia with the same variant observed in our probands, P7 and P8. Our probands had global developmental delay, progressive difficulty in walking, spasticity of lower limbs and contractures. Magnetic resonance imaging of brain had normal brain myelination and development in contrast to periventricular and deep white matter changes in the reported patient with the same variant. Vision and hearing were not evaluated in P7 and P8. WES revealed the previously reported variant, c.2T>G, p.Met1Arg in PLP1 in the siblings [9].

In conclusion, this report adds novel genotypes for rare subtypes of hereditary spastic paraplegias and further emphasizes the phenotypic and genetic heterogeneity of these disorders.

Acknowledgements We thank the families who cooperated with evaluation of their children and consented for participation in this study.

Funding This work was supported by Department of Health Research funded the project titled “Clinical and molecular characterization of leukodystrophies in Indian children” (V.25011/379/2015-GIA/HR) and National Institutes of Health funded project. ‘Genetic Diagnosis of Heritable Neurodevelopmental Disorders in India: Investigating the Use of Whole Exome Sequencing and Genetic Counseling to Address the High Burden of Neurodevelopmental Disorders’ (1R21NS094047-01).

Author contribution KMG and AS evaluated the patients, conceived the idea of the manuscript and planned the experiments. MH performed experiments and drafted the manuscript. SN evaluated the patients and contributed to the clinical reports. SB and KMG supervised the entire work. All authors read and approved the final manuscript.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

References

1. Klebe S, Stevanin G, Depienne C. Clinical and genetic heterogeneity in hereditary spastic paraplegias: from SPG1 to SPG72 and still counting. Rev Neurol (Paris). 2015;171:505–30.
2. Ruano L, Melo C, Silva MC, Coutinho P. The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies. Neuroepidemiology. 2014;42:174–83.
3. de Souza PV, de Rezende Pinto WB, de Rezende Batistella GN, Bortholin T, Oliveira AS. Hereditary spastic paraplegia: clinical and genetic hallmarks. Cerebellum. 2017;16:525–51.
4. Denton KR, Xu C, Shah H, Li XJ. Modeling axonal defects in hereditary spastic paraplegia with human pluripotent stem cells. Front Biol. 2016;11:339–54.
5. Girisha KM, Shukla A, Trujillano D, Bhavani GS, Hebbar M, Kadavgere R, et al. A homozygous nonsense variant in IFT52 is associated with a human skeletal ciliopathy. Clin Genet. 2016;90:536–9.
6. Guo Y, Ding X, Shen Y, Lyon GJ, Wang K. SeqMule: automated pipeline for analysis of human exome/genome sequencing data. Sci Rep. 2015;5:14283.
7. Danecek P, Auton A, Abecasis G, Albers CA, Banks E, DePristo MA, et al. The variant call format and VCF tools. Bioinformatics (Oxf, Engl). 2011;27:2156–8.

8. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med: Off J Am Coll Med Genet. 2015;17:405–24.

9. Hand CK, Bernard G, Dube MP, Shevell MI, Rouleau GA. A novel PLP1 mutation further expands the clinical heterogeneity at the locus. Can J Neurol Sci Le J Can Des Sci Neurol. 2012;39:220–4.

10. Abou Jamra R, Philippe O, Raas-Rothschild A, Eck SH, Graf E, Buchert R, et al. Adaptor protein complex 4 deficiency causes severe autosomal-recessive intellectual disability, progressive spastic paraplegia, shy character, and short stature. Am J Hum Genet. 2011;88:788–95.

11. Bauer P, Leshinsky-Silver E, Blumkin L, Schlipf N, Schroder C, Schicks J, et al. Mutation in the AP4B1 gene cause hereditary spastic paraplegia type 47 (SPG47). Neurogenetics. 2012;13:73–76.

12. Abdollahpour H, Alawi M, Kortum F, Beckstette M, Seemanova E, Komarek V, et al. An AP4B1 frameshift mutation in siblings with intellectual disability and spastic tetraplegia further delineates the AP-4 deficiency syndrome. Eur J Human Genet: EJhg. 2015;23:256–9.

13. Tuysuz B, Bilguvar K, Kocer N, Yalcinkaya C, Caglayan O, Gul E, et al. Autosomal recessive spastic tetraplegia caused by AP4M1 and AP4B1 gene mutation: expansion of the facial and neuroimaging features. Am J Med Genet A. 2014;164a:1677–85.

14. Ebrahimi-Fakhari D, Cheng C, Dies K, Diplock A, Pier DB, Ryan CS, et al. Clinical and genetic characterization of AP4B1-associated SPG47. Am J Med Genet A. 2018;176:311–8.

15. Bettencourt C, Salpietro V, Ethymiou S, Chelvan V, Hughes D, Pittman AM, et al. Genotype-phenotype correlations and expansion of the molecular spectrum of AP4M1-related hereditary spastic paraplegia. Orphanet J Rare Dis. 2017;12:172.

16. Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010;86:749–64.

17. Verkerk AJ, Schot R, Dunne B, Schellekens K, Swagemakers S, Bertoli-Avella AM, et al. Mutation in the AP4M1 gene provides a model for neuroaxonal injury in cerebral palsy. Am J Hum Genet. 2009;85:40–52.

18. Langouet M, Siquier-Pernet K, Sanquer S, Bole-Feyssot C, Nitschke P, Bodiart N, et al. Contiguous mutation syndrome in the era of high-throughput sequencing. Mol Genet & Genom Med. 2015;3:215–20.

19. Jameel M, Klar J, Tariq M, Moawia A, Altaf Malik N, Seema Waseem S, et al. A novel AP4M1 mutation in autosomal recessive cerebral palsy syndrome and clinical expansion of AP-4 deficiency. BMC Med Genet. 2014;15:133.

20. Najmabadi H, Hu H, Garshasbi M, Zemojtel T, Abedini SS, Chen W, et al. Deep sequencing reveals 50 novel genes for recessive cognitive disorders. Nature. 2011;478:57–63.

21. Alazami AM, Patel N, Shamseldin HE, Anazi S, Al-Dosari MS, Alzahrani F, et al. Accelerating novel candidate gene discovery in neurogenetic disorders via whole-exome sequencing of pre-screened multiplex consanguineous families. Cell Rep. 2015;10:148–61.